Sat. Sep 19th, 2020

Market and Financial News Aggregator

Gilead Sciences buying Immunomedics in $21 billion deal

1 min read

Shares of the cancer drug specialist Immunomedics have more than doubled before the opening bell, a day after its sale to Gilead Sciences for $21 billion was announced




2020-09-14 08:02:42


Read more from source here…

Leave a Reply